Literature DB >> 32839578

Immunotherapy for advanced thyroid cancers - rationale, current advances and future strategies.

Jena D French1,2.   

Abstract

In the past decade, the field of cancer immunotherapy has been revolutionized by immune checkpoint blockade (ICB) technologies. Success across a broad spectrum of cancers has led to a paradigm shift in therapy for patients with advanced cancer. Early data are now accumulating in progressive thyroid cancers treated with single-agent ICB therapies and combination approaches that incorporate ICB technologies. This Review discusses our current knowledge of the immune response in thyroid cancers, the latest and ongoing immune-based approaches, and the future of immunotherapies in thyroid cancer. Physiologically relevant preclinical mouse models and human correlative research studies will inform development of the next stage of immune-based therapies for patients with advanced thyroid cancer.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32839578     DOI： 10.1038/s41574-020-0398-9

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


  152 in total

Review 1.  Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; R T Kloos
Journal:  J Clin Endocrinol Metab       Date:  2001-04       Impact factor: 5.958

Review 2.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

3.  Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

Authors:  C Durante; N Haddy; E Baudin; S Leboulleux; D Hartl; J P Travagli; B Caillou; M Ricard; J D Lumbroso; F De Vathaire; M Schlumberger
Journal:  J Clin Endocrinol Metab       Date:  2006-05-09       Impact factor: 5.958

Review 4.  Advances in the follow-up of differentiated or medullary thyroid cancer.

Authors:  Rossella Elisei; Aldo Pinchera
Journal:  Nat Rev Endocrinol       Date:  2012-04-03       Impact factor: 43.330

5.  Definition and management of radioactive iodine-refractory differentiated thyroid cancer.

Authors:  Martin Schlumberger; Marcia Brose; Rosella Elisei; Sophie Leboulleux; Markus Luster; Fabian Pitoia; Furio Pacini
Journal:  Lancet Diabetes Endocrinol       Date:  2014-01-30       Impact factor: 32.069

Review 6.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

7.  The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis.

Authors:  Bo Lin; Haiqing Ma; Maoguang Ma; Zhicheng Zhang; Zicheng Sun; I-Yun Hsieh; Okose Okenwa; Haoyan Guan; Jie Li; Weiming Lv
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

Review 8.  Effectiveness of chemotherapy in advanced differentiated thyroid cancer: a systematic review.

Authors:  Ana Albero; Juliana Ester Lopéz; Alberto Torres; Luis de la Cruz; Tomas Martín
Journal:  Endocr Relat Cancer       Date:  2016-02       Impact factor: 5.678

9.  American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer.

Authors:  Robert C Smallridge; Kenneth B Ain; Sylvia L Asa; Keith C Bible; James D Brierley; Kenneth D Burman; Electron Kebebew; Nancy Y Lee; Yuri E Nikiforov; M Sara Rosenthal; Manisha H Shah; Ashok R Shaha; R Michael Tuttle
Journal:  Thyroid       Date:  2012-11       Impact factor: 6.568

10.  Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease.

Authors:  Naifa Lamki Busaidy; Maria E Cabanillas
Journal:  J Thyroid Res       Date:  2012-02-28
View more
  12 in total

Review 1.  Systemic Therapy in Thyroid Cancer.

Authors:  Amit Kumar Agrawal; Vanita Noronha; Vijay Patil; Nandini Menon; Akhil Kapoor; Anuradha Chougule; Pratik Chandrani; Kumar Prabhash
Journal:  Indian J Surg Oncol       Date:  2021-08-19

2.  Evaluate the diagnostic and prognostic value of NUSAP1 in papillary thyroid carcinoma and identify the relationship with genes, proteins, and immune factors.

Authors:  Tiantian Gao; Lei Zhao; Fan Zhang; Conghui Cao; Shuting Fan; Xiaoguang Shi
Journal:  World J Surg Oncol       Date:  2022-06-16       Impact factor: 3.253

3.  Improvement of Overall Survival Using TKIs as Salvage Therapy in Advanced Thyroid Carcinoma: Real-Life Data on a Single Center Experience.

Authors:  Lucia Brilli; Cristina Dalmiglio; Tania Pilli; Filomena Barbato; Fabio Maino; Marco Capezzone; Alessandra Cartocci; Maria Grazia Castagna
Journal:  J Clin Med       Date:  2021-01-20       Impact factor: 4.241

Review 4.  Emerging Biomarkers in Thyroid Practice and Research.

Authors:  Shipra Agarwal; Andrey Bychkov; Chan-Kwon Jung
Journal:  Cancers (Basel)       Date:  2021-12-31       Impact factor: 6.639

5.  Single-Cell RNA Sequencing Revealed a 3-Gene Panel Predicted the Diagnosis and Prognosis of Thyroid Papillary Carcinoma and Associated With Tumor Immune Microenvironment.

Authors:  Zuoyu Chen; Yizeng Wang; Dongyang Li; Yuting Le; Yue Han; Lanning Jia; Caigu Yan; Zhigang Tian; Wenbin Song; Fuxin Li; Ke Zhao; Xianghui He
Journal:  Front Oncol       Date:  2022-03-11       Impact factor: 6.244

6.  The Prognostic Value and Immunological Role of STEAP1 in Pan-Cancer: A Result of Data-Based Analysis.

Authors:  Chen Zhao; Kewei Xiong; Zhiqiang Ji; Fengming Liu; Xiangpan Li
Journal:  Oxid Med Cell Longev       Date:  2022-03-11       Impact factor: 6.543

7.  Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy.

Authors:  Ting Su; Furong Cheng; Jialong Qi; Yu Zhang; Shurong Zhou; Lei Mei; Shiwei Fu; Fuwu Zhang; Shuibin Lin; Guizhi Zhu
Journal:  Adv Sci (Weinh)       Date:  2022-06-16       Impact factor: 17.521

8.  Receptor-ligand pair typing and prognostic risk model for papillary thyroid carcinoma based on single-cell sequencing.

Authors:  Zhe Xu Cao; Xin Weng; Jiang Sheng Huang; Xia Long
Journal:  Front Immunol       Date:  2022-07-22       Impact factor: 8.786

9.  Identification and validation of an immune-related prognostic signature and key gene in papillary thyroid carcinoma.

Authors:  Rujia Qin; Chunyan Li; Xuemin Wang; Zhaoming Zhong; Chuanzheng Sun
Journal:  Cancer Cell Int       Date:  2021-07-15       Impact factor: 5.722

Review 10.  Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities.

Authors:  Loredana Lorusso; Virginia Cappagli; Laura Valerio; Carlotta Giani; David Viola; Luciana Puleo; Carla Gambale; Elisa Minaldi; Maria Cristina Campopiano; Antonio Matrone; Valeria Bottici; Laura Agate; Eleonora Molinaro; Rossella Elisei
Journal:  Int J Mol Sci       Date:  2021-03-18       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.